{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:22:02Z","timestamp":1790896922394,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>SARS-CoV-2 infection in immunocompromised hosts is challenging, and prolonged viral shedding can be a common complication in these patients. We describe the clinical, immunological, and virological course of a patient with eosinophilic granulomatosis with polyangiitis, who developed the status of long-term asymptomatic SARS-CoV-2 carrier for more than 7\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Over the study period, the patient underwent 20 RT-PCR tests for SARS-CoV-2 detection on nasopharyngeal swabs. In addition, viral cultures and genetic investigation of SARS-CoV-2 were performed. As for immunological assessment, serological and specific T-cell testing was provided at different time points.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Despite the patient showing a deep drug-induced B and T adaptive immunity impairment, he did not experience COVID-19 progression to severe complications, and the infection remained asymptomatic during the follow-up period, but he was not able to achieve viral clearance for more than 7\u00a0months. The infection was finally cleared by SARS-CoV-2-specific monoclonal antibody treatment, after that remdesivir and convalescent plasma failed in this scope. The genetic investigations evidenced that the infection was sustained by multiple viral subpopulations that had apparently evolved intra-host during the infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our case suggests that people with highly impaired B- and T-cell adaptive immunity can prevent COVID-19 progression to severe complications, but they may not be able to clear SARS-CoV-2 infection. Immunocompromised hosts with a long-term infection may play a role in the emergence of viral variants.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10875-022-01313-6","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T14:02:41Z","timestamp":1656770561000},"page":"1371-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-7118","authenticated-orcid":false,"given":"Michele","family":"Spinicci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Di Lauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Pilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seble Tekle","family":"Kiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Beccastrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Rossolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Annunziato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"2","key":"1313_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/cid\/ciaa863","volume":"72","author":"M Fung","year":"2021","unstructured":"Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;72(2):340\u201350.","journal-title":"Clin Infect Dis"},{"key":"1313_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"1313_CR3","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291\u20133.","journal-title":"N Engl J Med"},{"issue":"1","key":"1313_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","volume":"223","author":"JH Baang","year":"2021","unstructured":"Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23\u20137.","journal-title":"J Infect Dis"},{"key":"1313_CR5","doi-asserted-by":"crossref","unstructured":"Friedman MA, Winthrop KL. Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab. Ann Rheum Dis. 2021;80(8):1102\u20134.","DOI":"10.1136\/annrheumdis-2021-220088"},{"issue":"7","key":"1313_CR6","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","volume":"183","author":"VA Avanzato","year":"2020","unstructured":"Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901-1912.e9.","journal-title":"Cell"},{"key":"1313_CR7","first-page":"ciab538","volume":"22","author":"L Lodi","year":"2021","unstructured":"Lodi L, Moriondo M, Pucci A, et al. Chronic asymptomatic SARS-CoV-2 infection in the immunocompromised patient: new challenges and urgent needs. Clin Infect Dis. 2021;22:ciab538.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1313_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey L, Beyrer C, Cohen MS, et al. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385(6):562\u20136.","journal-title":"N Engl J Med"},{"key":"1313_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp SA, Collier DA, Datir RP, Ferreira IATM, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277\u201382.","journal-title":"Nature"},{"key":"1313_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ijid.2020.10.072","volume":"102","author":"A Piralla","year":"2021","unstructured":"Piralla A, Ricchi M, Cusi MG, et al. Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: is prolonged quarantine always justified? Int J Infect Dis. 2021;102:299\u2013302.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"1313_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3390\/vaccines9050517","volume":"9","author":"G Anichini","year":"2021","unstructured":"Anichini G, Terrosi C, Gori Savellini G, Gandolfo C, Franchi F, Cusi MG. Neutralizing antibody response of vaccinees to SARS-CoV-2 variants. Vaccines (Basel). 2021;9(5):517.","journal-title":"Vaccines (Basel)"},{"key":"1313_CR12","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg. 1938;27:493\u20137.","journal-title":"Am J Hyg"},{"issue":"7","key":"1313_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","volume":"222","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222(7):1103\u20137.","journal-title":"J Infect Dis"},{"key":"1313_CR14","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/bjh.16981","volume":"190","author":"E Clark","year":"2020","unstructured":"Clark E, Guilpain P, Filip IL, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol. 2020;190:e154\u20136.","journal-title":"Br J Haematol"},{"issue":"12","key":"1313_CR15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3390\/v12121438","volume":"12","author":"F Di Giallonardo","year":"2020","unstructured":"Di Giallonardo F, Duchene S, Puglia I, et al. Genomic epidemiology of the first wave of SARS-CoV-2 in Italy. Viruses. 2020;12(12):1438.","journal-title":"Viruses"},{"key":"1313_CR16","doi-asserted-by":"publisher","first-page":"105038","DOI":"10.1016\/j.meegid.2021.105038","volume":"95","author":"K Laiton-Donato","year":"2021","unstructured":"Laiton-Donato K, Franco-Mu\u00f1oz C, \u00e1lvarez-D\u00edaz DA, et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol. 2021;95:105038.","journal-title":"Infect Genet Evol"},{"issue":"3","key":"1313_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463-476.e6.","journal-title":"Cell Host Microbe"},{"issue":"5","key":"1313_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284-1294.e9.","journal-title":"Cell"},{"key":"1313_CR19","doi-asserted-by":"crossref","unstructured":"Naveca F, Nascimento V, Souza V, et al. Spread of gamma (P.1) sub-lineages carrying spike mutations close to the furin cleavage site and deletions in the N-terminal domain drives ongoing transmission of SARS-CoV-2 in Amazonas, Brazil. Microbiol Spectr. 2022;10(1):e0236621.","DOI":"10.1128\/spectrum.02366-21"},{"issue":"2","key":"1313_CR20","doi-asserted-by":"publisher","first-page":"e0247196","DOI":"10.1371\/journal.pone.0247196","volume":"16","author":"CL Loureiro","year":"2021","unstructured":"Loureiro CL, Jaspe RC, D\u00b4angelo P, et al. SARS-CoV-2 genetic diversity in Venezuela: predominance of D614G variants and analysis of one outbreak. PLoS One. 2021;16(2):e0247196.","journal-title":"PLoS One"},{"issue":"7","key":"1313_CR21","doi-asserted-by":"publisher","first-page":"ofab295","DOI":"10.1093\/ofid\/ofab295","volume":"8","author":"I Monrad","year":"2021","unstructured":"Monrad I, Sahlertz SR, Nielsen SSF, et al. Persistent severe acute respiratory syndrome coronavirus 2 infection in immunocompromised host displaying treatment induced viral evolution. Open Forum Infect Dis. 2021;8(7):ofab295.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"1313_CR22","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/infdis\/jiab622","volume":"225","author":"V Nussenblatt","year":"2022","unstructured":"Nussenblatt V, Roder AE, Das S, et al. Yearlong COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B-cell depletion. J Infect Dis. 2022;225(7):1118\u201323.","journal-title":"J Infect Dis"},{"issue":"11","key":"1313_CR23","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s00277-021-04662-1","volume":"100","author":"H Levavi","year":"2021","unstructured":"Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol. 2021;100(11):2805\u201312.","journal-title":"Ann Hematol"},{"key":"1313_CR24","doi-asserted-by":"publisher","first-page":"763412","DOI":"10.3389\/fimmu.2021.763412","volume":"12","author":"A Furlan","year":"2021","unstructured":"Furlan A, Forner G, Cipriani L, et al. COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challengE. Front Immunol. 2021;12:763412.","journal-title":"Front Immunol"},{"key":"1313_CR25","doi-asserted-by":"publisher","first-page":"102185","DOI":"10.1016\/j.msard.2020.102185","volume":"42","author":"P Montero-Escribano","year":"2020","unstructured":"Montero-Escribano P, Mat\u00edas-Guiu J, G\u00f3mez-Iglesias P, Matias-Guiu JA, et al. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185.","journal-title":"Mult Scler Relat Disord"},{"key":"1313_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijid.2021.04.068","volume":"107","author":"A D'abramo","year":"2021","unstructured":"D\u2019abramo A, Vita S, Maffongelli G, et al. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach. Int J Infect Dis. 2021;107:247\u201350.","journal-title":"Int J Infect Dis"},{"key":"1313_CR27","doi-asserted-by":"crossref","unstructured":"Spinicci M, Mazzoni A, Borchi B, et al. AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection. Eur J Immunol. 2022;52(2):352\u20135.","DOI":"10.1002\/eji.202149574"},{"issue":"1","key":"1313_CR28","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1038\/s41467-020-19761-2","volume":"11","author":"MS Buckland","year":"2020","unstructured":"Buckland MS, Galloway JB, Fhogartaigh CN, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020;11(1):6385.","journal-title":"Nat Commun"},{"issue":"8","key":"1313_CR29","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/trf.16525","volume":"61","author":"JW Senefeld","year":"2021","unstructured":"Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021;61(8):2503\u201311.","journal-title":"Transfusion"},{"issue":"21","key":"1313_CR30","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","volume":"385","author":"FK Korley","year":"2021","unstructured":"Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with Covid-19. N Engl J Med. 2021;385(21):1951\u201360.","journal-title":"N Engl J Med"},{"issue":"11","key":"1313_CR31","doi-asserted-by":"publisher","first-page":"e2136246","DOI":"10.1001\/jamanetworkopen.2021.36246","volume":"4","author":"F Menichetti","year":"2021","unstructured":"Menichetti F, Popoli P, Puopolo M, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open. 2021;4(11):e2136246.","journal-title":"JAMA Netw Open"},{"key":"1313_CR32","doi-asserted-by":"crossref","unstructured":"Choudhary MC, Crain CR, Qiu X, et al. SARS-CoV-2 sequence characteristics of COVID-19 persistence and reinfection Clin Infect Dis. 2021;ciab380.","DOI":"10.1101\/2021.03.02.21252750"},{"issue":"6534","key":"1313_CR33","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.abf6950","volume":"371","author":"KR Mccarthy","year":"2021","unstructured":"Mccarthy KR, Rennick LJ, Nambulli S, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371(6534):1139\u201342.","journal-title":"Science"},{"key":"1313_CR34","doi-asserted-by":"crossref","unstructured":"Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021;ciab912.","DOI":"10.1093\/cid\/ciab912"},{"key":"1313_CR35","doi-asserted-by":"crossref","unstructured":"Verderese JP, Stepanova M, Lam B, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID-19: a real-world experience. Clin Infect Dis. 2021;ciab579.","DOI":"10.1093\/cid\/ciab579"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-022-01313-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T19:21:04Z","timestamp":1668799264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-022-01313-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s10875-022-01313-6","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the ethical principles of the Declaration of Helsinki and with the International Conference on Harmonization Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The patient provided signed informed consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}